PT - JOURNAL ARTICLE AU - Ruth K Topless AU - Ralph Green AU - Sarah L. Morgan AU - Philip C Robinson AU - Tony R Merriman AU - Angelo L. Gaffo TI - FOLIC ACID AND METHOTREXATE USE AND THEIR ASSOCIATION WITH COVID-19 DIAGNOSIS AND MORTALITY: AN ANALYSIS FROM THE UK BIOBANK AID - 10.1101/2022.02.10.22270804 DP - 2022 Jan 01 TA - medRxiv PG - 2022.02.10.22270804 4099 - http://medrxiv.org/content/early/2022/02/14/2022.02.10.22270804.short 4100 - http://medrxiv.org/content/early/2022/02/14/2022.02.10.22270804.full AB - Importance Folate metabolism is implicated in SARS-CoV-2 infectivity. Medication affecting folate metabolism may influence the risk of COVID-19 diagnosis and outcomes.Objective to determine if methotrexate (an antifolate) or folic acid prescription were associated with differential risk, for COVID-19 diagnosis or mortality.Design, Setting, and Participants Case-control analysis of COVID-19 from the population-based UK Biobank (UKBB) cohort. Updated medical information was retrieved on the 13th December 2021. Data from 380,380 UKBB participants with general practice prescription data for 2019 to 2021 were used. Criteria for COVID-19 diagnosis were 1) a positive SARS-CoV-2 test or 2) ICD-10 code for confirmed COVID-19 (U07.1) or probable COVID-19 (U07.2) in hospital records, or death records. By these criteria 26,003 individuals were identified with COVID-19 of whom 820 were known to have died from COVID-19. Logistic regression statistical models were adjusted for age sex, ethnicity, Townsend deprivation index, BMI, smoking status, presence of rheumatoid arthritis, sickle cell disease, use of anticonvulsants, statins and iron supplements.Exposures Prescription of folic acid and/or methotrexate.Main outcomes and measures The outcomes of COVID-19 diagnosis and COVID-19 related mortality were analyzed by multivariable logistic regression. The odds ratios from different exposures were compared.Results Compared with people prescribed neither folic acid nor methotrexate, people prescribed folic acid supplementation had increased risk of diagnosis of COVID-19 (OR 1.51 [1.42 ; 1.61]). The prescription of methotrexate with or without folic acid was not associated with COVID-19 diagnosis (P≥0.18). People prescribed folic acid supplementation had positive association with death after a diagnosis of COVID-19 (OR 2.64 [2.15 ; 3.24]) in a fully adjusted model. The prescription of methotrexate in combination with folic acid was not associated with an increased risk for COVID-19 related death (1.07 [0.57 ; 1.98]).Conclusions and Relevance We report increased risk for COVID-19 diagnosis and COVID-19-related death for people prescribed folic acid supplementation. Prescription and use of supplemental folic acid may confer increased risk of infection with SARS-CoV-2 and increased risk of death resulting from COVID-19. Our results indicate that methotrexate attenuates an increased risk for COVID-19 diagnosis and death conferred by folic acid.Question Does folate supplementation and/or methotrexate use affect the risk COVID-19 diagnosis and COVID-19 associated mortality?Findings In this epidemiological analysis from the UK Biobank, folic acid supplementation was associated with a 1.5-fold increased risk of COVID-19 diagnosis and a 2.6-fold increased risk of COVID-19 associated mortality. Methotrexate use might attenuate an increased risk for COVID-19 diagnosis and death conferred by folic acid.Meaning Folic acid supplementation appears to be associated with increased risk for COVID-19 diagnosis and associated mortality while methotrexate use attenuated this riskCompeting Interest StatementPCR reports personal fees from Abbvie, Atom Biosciences, Eli Lilly, Gilead, Janssen, Novartis, UCB, Roche, Pfizer; meeting attendance support from BMS, Pfizer and UCB Pharma and grant funding from Janssen, Novartis, Pfizer and UCB Pharma, all outside the submitted work. AG reports personal fees from SOBI, Selecta and honoraria from UptoDate, Inc. outside the submitted work. All other authors have no declarations of interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involves only openly available data from human participants, which can be obtained from the UK Biobank.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll summary data produced in the present study are available upon reasonable request to the authors. The authors are unable to share the individual level data from the UK Biobank.